ABSTRACT
IMPORTANCE Genes and lifestyle factors influence progression to advanced age-related macular degeneration (AAMD). However, the impact of genetic and behavioral factors on age when this transition occurs has not been evaluated prospectively.
OBJECTIVE To determine whether genetic and environmental factors are associated with age of progression to AAMD and to quantify the effect on age.
DESIGN, SETTING, AND PARTICIPANTS Longitudinal progression to AAMD was based on the severity scale in the Age-Related Eye Disease Study database. Progression was defined as an eye that transitioned from non-advanced dry AMD without any evidence of geographic atrophy (GA) (levels 1-8) to any GA or evidence of neovascularization (NV) or both (levels ≥9) during 13 years follow up. Genotypes were determined from DNA samples.
MAIN OUTCOME AND MEASURES A stepwise selection of genetic variants with the eye as the unit of analysis, using age as the time scale, yielded 11 genetic variants associated with overall progression, adjusting for sex, education, smoking history, BMI, baseline severity scale, and AREDS treatment. Multivariate analysis was also performed to calculate the effect of genetic and behavioral factors on age of progression.
RESULTS Among 5421 eyes, 1206 progressed. Genetic variants associated with progression to AAMD were in the complement, immune, inflammatory, lipid, extracellular matrix, DNA repair and protein binding pathways. Three of these variants were significantly associated with earlier age of progression, adjusting for other covariates: CFH R1210C (P=0.019) with 4.7 years earlier age at progression among carriers of this mutation, C3 K155Q (P=0.011) with 2.44 years earlier for carriers, and ARMS2/HTRA1 A69S (P=0.012) with 0.67 years earlier per allele. Subjects who were smokers (P<. 001) or had high BMI (P=0.006) also had an earlier age at progression (4.1 years and 1.4 years, respectively).
CONCLUSIONS Carriers of rare variants in the complement pathway and a common risk allele in ARMS2/HTRA1 develop advanced AMD at an earlier age, and unhealthy behaviors including smoking and higher body mass index lead to earlier age of progression to AAMD.
Question Are genetic and modifiable factors associated with earlier age of developing advanced AMD?
Findings In this prospective analysis of 5421 eyes with non-advanced AMD at baseline, 1206 developed advanced stages of AMD. Smoking together with a higher BMI led to 5.5 years earlier progression to advanced disease, and genetic burden, determined by rare and common variants, lowered age of progression by up to an additional 6.0 years, adjusting for all covariates.
Meaning Modifiable factors alter age when advanced AMD and associated visual loss occurs, and genetic susceptibility impacts age of this transition. Results underscore the importance of both nature and nurture on earlier progression to advanced disease leading to a longer duration of disease and treatment burden.
Submitted as ARVO abstract December, 2019: abstract citation: Widjajahakim R, Rosner B, Seddon J; Rare and Common Genetic Variants and Behavioral Modifiable Factors Are Associated with Earlier Age of Progression to Advanced AMD. Invest. Ophthalmol. Vis. Sci. 2020;61(7):2436).
Competing Interest Statement
JS reports personal fees and other from Gemini Therapeutics, Inc., other from THEA Pharmaceuticals, outside the submitted work.
Funding Statement
Supported in part by NIH R01-EY011309, R01-EY028602, R01-EY022445, American Macular Degeneration Foundation, Northampton, MA, The Macular Degeneration Center of Excellence, University of Massachusetts Medical School, Department of Ophthalmology and Visual Sciences, Worcester, MA.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used de-identified public data and the project was approved under University Of Massachusetts IRB.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Supported in part by NIH R01-EY011309, R01-EY028602, R01-EY022445, American Macular Degeneration Foundation, Northampton, MA, The Macular Degeneration Center of Excellence, University of Massachusetts Medical School, Department of Ophthalmology and Visual Sciences, Worcester, MA.
Data Availability
Data is based on publicly available data from the U.S. National Institute of Health.
